You just read:

The American Journal of Respiratory and Critical Care Medicine Publishes Study of Spyryx Biosciences' SPX-101, A Novel ENaC-Targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport

News provided by

Spyryx Biosciences, Inc.

09 May, 2017, 13:00 ET